

Resource Summary Report

Generated by [NIF](#) on Sep 10, 2026

Purified anti-CD68

RRID:AB_2616797

Type: Antibody

Proper Citation

BioLegend Cat# 916104, RRID:AB_2616797

Antibody Information

URL: http://antibodyregistry.org/AB_2616797

Proper Citation: BioLegend Cat# 916104, RRID:AB_2616797

Target Antigen: CD68

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: IHC-P, ICC, IP, WB

Antibody Name: Purified anti-CD68

Description: This monoclonal targets CD68

Target Organism: human

Clone ID: Clone KP1

Antibody ID: AB_2616797

Vendor: BioLegend

Catalog Number: 916104

Record Creation Time: 20231110T034920+0000

Record Last Update: 20260831T223704+0000

Ratings and Alerts

- Used for cytometry time of flight assay by the Human Islet Research Network community. Contact(s): [Bernd Bodenmiller](#) - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for Purified anti-CD68.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 21 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Nguyen YTM, et al. (2026) Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer. Cell reports. Medicine, 102938.

Vuong L, et al. (2026) Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma. Cancer cell, 44(7), 1477.

Giordano FA, et al. (2026) L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial. Nature communications, 17(1).

Zitti B, et al. (2026) Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity. Immunity, 59(1), 161.

Nebeling FC, et al. (2026) Microglia-glioblastoma crosstalk mediates glioblastoma invasion at the far infiltration zone. Immunity, 59(4), 1075.

Wei S, et al. (2026) A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma. Cell reports. Medicine, 7(4), 102716.

Cheng Y, et al. (2026) A conserved eIF1A+ luminal cell-centered hypoxic and "cold" tumor microenvironment promotes pan-subtype prostate cancer progression. Cell reports. Medicine, 7(2), 102619.

Pereira MJ, et al. (2025) Depot-specific metabolic and inflammatory profiles in perirenal and renal sinus adipose tissue. Molecular medicine (Cambridge, Mass.), 31(1), 262.

Acha-Sagredo A, et al. (2025) A constitutive interferon-high immunophenotype defines response to immunotherapy in colorectal cancer. Cancer cell, 43(2), 292.

Oh J, et al. (2025) Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer. Cell reports. Medicine, 6(5), 102100.

Giordano FA, et al. (2024) L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial. *Nature communications*, 15(1), 4210.

Liu W, et al. (2024) SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8⁺ T cell activation. *Cell metabolism*, 36(10), 2245.

Ak Ç, et al. (2024) Multiplex imaging of localized prostate tumors reveals altered spatial organization of AR-positive cells in the microenvironment. *iScience*, 27(9), 110668.

Pozniak J, et al. (2024) A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma. *Cell*, 187(1), 166.

Luo W, et al. (2023) Distinct immune microenvironment of lung adenocarcinoma in never-smokers from smokers. *Cell reports. Medicine*, 4(6), 101078.

Ruf B, et al. (2023) Tumor-associated macrophages trigger MAIT cell dysfunction at the HCC invasive margin. *Cell*, 186(17), 3686.

Mascharak S, et al. (2023) Desmoplastic stromal signatures predict patient outcomes in pancreatic ductal adenocarcinoma. *Cell reports. Medicine*, 4(11), 101248.

Johnson BE, et al. (2022) An omic and multidimensional spatial atlas from serial biopsies of an evolving metastatic breast cancer. *Cell reports. Medicine*, 3(2), 100525.

Gide TN, et al. (2019) Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. *Cancer cell*, 35(2), 238.

Wagner J, et al. (2019) A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. *Cell*, 177(5), 1330.